US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Abstract, Snapshot, Market Analysis & Market Definition: Global Amyloidosis Treatment Market The global amyloidosis treatment market size was valued at USD 3.6 billion in 2017 and is anticipated to exhibit a CAGR of 7.2% over the forecast period. Increased adoption of novel targeted therapies and transplantations, emergence of biologics, and rising geriatric population are some of the factors that will collectively drive the market. Amyloidosis is a group of rare diseases characterized by the buildup of amyloids (aggregates of proteins) that are folded in an incorrect way and get deposited in several organs. The most commonly affected organs include the heart, kidneys, liver, soft tissue, peripheral nervous system, and the gastrointestinal tract. Organ involvement can be different among patients; however, the reason for this difference remains unknown. Amyloidosis can be categorized as either localized or systemic, based on if it only gathers in a specific part of the body or if it is simultaneously located in different parts of the body. AL, AA, and ATTR amyloidosis are the most common systemic variants of this disease. In U.S., AL amyloidosis is the most common type, with approximately 3,900 new cases diagnosed every year. The median age of diagnosis for this disease variant is mid-60. Its annual incidence is about 14 cases per million people in western countries, which is approximately one fifth of that of multiple myeloma, a blood cancer caused by clonal plasma cells in the bone marrow. Furthermore, symptoms such as weight loss, fatigue, edema, and paresthesia often overlap with other common diseases, making its diagnosis difficult. AL amyloidosis is associated with a high mortality rate of approximately 35% within one year of diagnosis, with a median survival between 12 and 18 months. The overall survival in this disease is poorer than multiple myeloma, which shares certain similarities with AL amyloidosis in relation to both pathogenesis and treatment options. Market Segmentation, Outlook & Viewpoint: Global Amyloidosis Treatment Market Treatment Market Segmentation & Outlook (Revenue, USD Million, 2017 - 2025) Chemotherapy Supportive Care Surgery Stem Cell Transplant Targeted Therapy Key Players, Recent Developments & Regional Insights: Global Amyloidosis Treatment Market Currently available amyloidosis treatments provide symptomatic relief and palliative care. These include chemotherapy, targeted therapy, supportive care, surgery, and stem cell transplantation. A high-dose chemotherapy followed by autologous stem cell transplant remains the preferred therapy for low-risk patients in U.S. due to high rate of hematological remission and long-term disease control following treatment. Targeted therapies and stem cell transplants are gaining traction in developed countries. However, majority of the world’s population does not have access to sufficient healthcare infrastructure to ensure rapid diagnosis and treatment in low-income economies. Additionally, one of the major challenges for the amyloidosis treatment market is high cost of these therapies, which creates a financial burden for patients based in underdeveloped regions. Targeted therapy is likely to demonstrate the fastest growth in the global market, followed by stem cell transplant and surgery.It is expected that chemotherapy and supportive care will lose market share over the forecast period due to adverse side effects and lower efficacy. Country Insights U.S. dominated the global market with a share of more than 27.0% in 2017, followed by France and U.K. Although France is projected to exhibit the highest CAGR among the seven major markets, U.S. is expected to retain its market lead throughout the forecast period. Potential launch of pipeline drugs, increased adoption of novel therapeutics, and high cost of treatment in U.S. are a few factors responsible for its dominant share. EU5 countries together accounted for more than 60.0% of the market in 2017. This is owing to the fact that two of the three late-stage drugs have been approved for amyloidosis treatment in Europe. Emerging markets for amyloidosis such as China, Sweden, Portugal, Turkey, South Africa, Brazil, Mexico, Saudi Arabia, and India are expected to show attractive growth over the forecast period due to encouraging government policies, increased investment, and improved healthcare infrastructure. The large population base in these countries with low per capita income have resulted in high demand for affordable healthcare, which will drive the rise of chemotherapy generics in this market. There is a critical need for curative treatment options with improved efficacy. Amyloidosis Treatment Market Share Insights Key players operating in the market include Pfizer, Inc.; Ionis Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Ltd.; Johnson and Johnson Pvt. Ltd.; and Alnylam Pharmaceuticals, Inc. Alnylam and Ionis are projected to dominate the competitive landscape post the worldwide approval of their pipeline candidates - Tegsedi and Onpattro, respectively. Pfizer also holds promise of gaining significant market share by 2025, supported by strong sales of Vyndaqel. Late-stage pipeline drugs such as Johnson & Johnson’s Darzalex and Takeda’s Ninlaro have demonstrated favorable safety and efficacy results. Some of the other companies actively investing in R&D of amyloidosis treatment are GlaxoSmithKline Pharmaceuticals Ltd.; Celgene Corp; Eidos Therapeutics, Inc.; Corino Therapeutics, Inc.; Spectrum Pharmaceuticals, Inc.; Prothena Corporation plc; Caelum Biosciences, Inc.; Proclara Biosciences Inc.; Arcturus Therapeutics Ltd.; and Neurimmune Holding AG. In the near future, the market will witness the introduction of biologics such as GSK2398852, Darzalex, PRX 004, CAEL101, LUNAR-101, and NI 301. Key Insights Covered: Global Amyloidosis Treatment Market 1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Amyloidosis Treatment industry. 2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Amyloidosis Treatment industry. 3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Amyloidosis Treatment industry. 4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Amyloidosis Treatment industry. 5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Amyloidosis Treatment industry. Research Methodology: Global Amyloidosis Treatment Market
- Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
- Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
- Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other
Table of Contents Chapter 1 Report Scope 1.1 Treatment Scope 1.2 Country Scope 1.3 Estimates and Forecast TimelineChapter 2 Methodology 2.1 Research Methodology 2.1.1 Information procurement 2.2 Information or Data Analysis 2.3 Market Formulation & Validation 2.4 List of Sources 2.5 List of AbbreviationsChapter 3 Objectives 3.1 Objective - 1: Understanding the market dynamics 3.2 Objective - 2: Understanding the trends & variables in the individual countries 3.3 Objective - 3: Understanding the attributes such as strategy framework 3.4 Objective - 4: Understanding | read more...